Global Markets Direct’s, 'Diabetic Complications - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Complications, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Complications. Diabetic Complications - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Diabetic Complications. - A review of the Diabetic Complications products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Complications pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Diabetic Complications. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Complications pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Diabetic Complications - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Diabetic Complications Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Diabetic Complications 7 Diabetic Complications Therapeutics under Development by Companies 9 Mid Clinical Stage Products 10 Comparative Analysis 10 Discovery and Pre-Clinical Stage Products 11 Comparative Analysis 11 Diabetic Complications Therapeutics - Products under Development by Companies 12 Companies Involved in Diabetic Complications Therapeutics Development 13 Tissue Repair Company 13 Torrent Pharmaceuticals Limited 14 Diabetology Limited 15 NOXXON Pharma AG 16 MacuCLEAR, Inc. 17 Adamed Sp. z o.o. 18 Centocor Ortho Biotech, Inc. 19 Amunix, Inc. 20 Diabetic Complications - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 NOX-E-36 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 EPC Therapy - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 HO-1 Activator - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 VPI-2690-B - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 AMX-888 - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 TRC-4186 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 Oral C-Peptide Analogs - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 Migration Stimulating Factor - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 Diabetic Complications Therapeutics - Drug Profile Updates 37 Diabetic Complications Therapeutics - Dormant Products 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables
Number of Products Under Development for Diabetic Complications, H1 2013 7 Products under Development for Diabetic Complications - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Mid Clinical Stage Development, H1 2013 10 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 11 Products under Development by Companies, H1 2013 12 Tissue Repair Company, H1 2013 13 Torrent Pharmaceuticals Limited, H1 2013 14 Diabetology Limited, H1 2013 15 NOXXON Pharma AG, H1 2013 16 MacuCLEAR, Inc., H1 2013 17 Adamed Sp. z o.o., H1 2013 18 Centocor Ortho Biotech, Inc., H1 2013 19 Amunix, Inc., H1 2013 20 Assessment by Monotherapy Products, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 25 Diabetic Complications Therapeutics - Drug Profile Updates 37 Diabetic Complications Therapeutics - Dormant Products 38
List of Figures
Number of Products under Development for Diabetic Complications, H1 2013 7 Products under Development for Diabetic Complications - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Mid Clinical Stage Products, H1 2013 10 Discovery and Pre-Clinical Stage Products, H1 2013 11 Assessment by Monotherapy Products, H1 2013 21 Assessment by Route of Administration, H1 2013 22 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Molecule Type, H1 2013 24 Assessment by Stage and Molecule Type, H1 2013 25